The Medicines Patent Pool and Otsuka Sign Memorandum of Understanding for Paediatric Formulations of Delamanid for Multidrug-Resistant Tuberculosis
801  

The Medicines Patent Pool and Otsuka Sign Memorandum of Understanding for Paediatric Formulations of Delamanid for Multidrug-Resistant Tuberculosis

The Medicines Patent Pool (MPP) announced that it has signed a Memorandum of Understanding (MoU) with Otsuka to accelerate the development and manufacturing of, and access to, paediatric formulations containing delamanid for multidrug-resistant tuberculosis (MDR-TB). Delamanid 50mg tablet was recently added to the World Health Organization’s Essential ...

October 12, 2017
News  
The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir
918  

The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir

As part of a novel, once-daily, single-tablet HIV treatment, bictegravir could offer new option for people living with HIV in low- and middle-income countries Geneva, 4 October 2017 — The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under ...

October 04, 2017
News